Neurogen Biomarking will present novel validation data on at-home p-tau 217 blood testing for Alzheimer's disease at the upcoming Alzheimer's Association International Conference (AAIC) in Toronto, Canada. Chief Scientific Officer Elisabeth Thijssen, PhD will report the results of a study designed to validate remote collection of blood biomarkers for Alzheimer's disease and related disorders.
The presentation has been selected for AAIC's Featured Research Session (FRS), which debuts and discusses innovative and impactful research findings, drawing together multiple studies that share a common focus. AAIC has also designated Neurogen's presentation as a Clinical Pearl for its real-world relevance to dementia diagnosis and care.
Conference Presentation Details
The presentation is scheduled for Monday, July 28 at 2 p.m. EDT in Hall F. The session will be formatted as a podium presentation followed by a Q&A period, focusing on the scientific session theme of "Remote Collection of Blood Biomarkers for Alzheimer's disease and related disorders."
Advancing Accessible Brain Health Testing
Neurogen Biomarking positions itself on a global mission to provide equitable access to brain health care. The company offers what it describes as the first at-home blood biomarker test for phosphorylated tau-217 (p-tau217) using proprietary blood collection technology. This testing approach is combined with advanced digital cognitive testing, with results guided by board-certified neurologists via telehealth.
The company's vision centers on delivering accessible technology, actionable insights, and pathways to precision-based proactive care to support early detection and care for Mild Cognitive Impairment (MCI) and dementia associated with Alzheimer's disease. Neurogen was founded by award-winning neurologist Dr. Rany Aburashed and is guided by world-renowned brain health experts.
Clinical Significance
The designation of Neurogen's presentation as a Clinical Pearl by AAIC underscores the potential real-world impact of remote biomarker collection for dementia diagnosis and care. The validation study results being presented could represent a significant step toward making Alzheimer's disease biomarker testing more accessible to patients who may face barriers to traditional clinical testing environments.
